All In Biotech

Drug Trial Radar · NCT00174993

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy

Last checked: Nov 20, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,373 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,373

Actual

Start

May 2001

Primary completion

Jan 2005

Study completion Jan 2005

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 35 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.

Conditions

  • Diabetes Mellitus

Interventions

  • PioglitazoneDrug

    Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.

  • PlaceboDrug

    Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.Time frame: At First Occurrence

Locations

19 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Multiple Cities, Austria

  • Site not named

    Multiple Cities, Belgium

  • Site not named

    Multiple Cities, Czechia

  • Site not named

    Multiple Cities, Denmark

  • Site not named

    Multiple Cities, Estonia

  • Site not named

    Multiple Cities, Finland

  • Site not named

    Multiple Cities, France

  • Site not named

    Multiple Cities, Germany

  • Site not named

    Multiple Cities, Hungary

  • Site not named

    Multiple Cities, Italy

  • Site not named

    Multiple Cities, Latvia

  • Site not named

    Multiple Cities, Lithuania

  • Site not named

    Multiple Cities, Netherlands

  • Site not named

    Multiple Cities, Norway

  • Site not named

    Multiple Cities, Poland

  • Site not named

    Multiple Cities, Slovakia

  • Site not named

    Multiple Cities, Sweden

  • Site not named

    Multiple Cities, Switzerland

  • Site not named

    Multiple Cities, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.